openFDA
Cure8 regulatory brief
Dexamethasone FDA label update (2026-11-04)
Medications
Steroids
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Inflammatory bowel disease
Ulcerative colitis
Why This Matters
The label confirms dexamethasone is listed as an option to manage acute periods of Crohn’s disease (regional enteritis) and ulcerative colitis and provides dosing/tapering guidance relevant to patients and clinicians. It’s an official regulatory resource for prescribing and safety information.
Who Should Pay Attention
Patients with Crohn’s disease or ulcerative colitis prescribed corticosteroids; clinicians managing IBD; pharmacists and caregivers.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This DailyMed entry is a regulatory drug-label document for dexamethasone. It lists approved indications across many specialties, including a line noting dexamethasone can be used “to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis,” and shows recommended dose ranges and tapering advice.
The label emphasizes individualized dosing and gradual withdrawal after long-term therapy. If you use corticosteroids for IBD, this label is a formal source for dexamethasone dosing options and standard safety precautions, but it does not replace individualized medical advice from your clinician.
Keep In Mind
This is a regulatory drug-label (DailyMed) entry summarizing approved indications and dosing. It is not a practice guideline or clinical trial report. Individual treatment decisions should be made with a clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorPD-Rx Pharmaceuticals, Inc.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedNov 4, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dexamethasone Intensol FDA label update (2026-08-21)
This is the official FDA label text for dexamethasone, so it clarifies approved uses and gives practical dosing and tapering guidance. It explicitly names "regional enteritis and ulcerative colitis," which matters to...
Triamcinolone Acetonide FDA label update (2026-08-14)
The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...
Prednisone FDA label update (2026-07-31)
Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.